NCT02613312

Terminated

Chemotherapy Followed by Surgery and Neoadjuvant Hemothoraci...

Mayo Clinic Source

Mayo Clinic

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

15-007645

Secondary identifiers

NCI-2024-02057

REGISTRY · CTRP (Clinical Trials Reporting Program)

Study Type

observational

Actual enrollment (reported)

8

Locations

1 country

Sites

1

Timeline

Study Start

March 18, 2016

Actual (reported)

Primary Completion

October 5, 2020

Actual (reported)

Study Completion

October 5, 2020

Actual (reported)

Brief Summary

The purpose of this study is to determine the response rate and overall survival in patients that have been diagnosed with mesothelioma and will undergo chemotherapy, surgery and intensity modified radiation therapy (IMRT) as part of their standard of care.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: terminated
Actual enrollment (reported): 8 participants
Study completion date: October 5, 2020
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
November 20, 2015
Actual (reported)
First Posted
November 24, 2015
Actual (reported)
Study Start
March 18, 2016
Actual (reported)
Primary Completion
October 5, 2020
Actual (reported)
Study Completion
October 5, 2020
Actual (reported)

Last Updated: July 30, 2024
Status Verified: July 2024
Last Update Submitted: July 29, 2024

Conditions

Mesothelioma Solitary Fibrous Tumor of the Pleura

Outcome Measures

Primary Outcomes (1)

Overall Survival (OS)
OS is defined as the length of time from study enrollment to death by any cause. Survival status of patients will be monitored every 6 months
2 years

Secondary Outcomes (1)

Progression free survival (PFS) as evidenced by CT scan review
2 years

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients receiving treatment at the Mayo Clinic Rochester that have been diagnosed with mesothelioma and will undergo chemotherapy followed by surgery and then IMRT as their standard of care.

You may qualify if:

Subject provides informed consent

Sponsors & Collaborators

Mayo Clinic
Otherlead

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

MeSH Terms

Conditions

MesotheliomaSolitary Fibrous Tumor, Pleural

Condition Hierarchy (Ancestors)

AdenomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, MesothelialSolitary Fibrous TumorsNeoplasms, Fibrous TissueNeoplasms, Connective TissueNeoplasms, Connective and Soft TissuePleural NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by Site

Study Officials

Dennis Wigle, MD, PhD
Mayo Clinic
PRINCIPAL INVESTIGATOR

Enrollment

8 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

November 20, 2015

First Posted

November 24, 2015

Study Start

March 18, 2016

Actual (reported)

NCT02592551

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Phase 2Completed

NCT03683680

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

Not ApplicableRecruiting

NCT02798536

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Phase 1Completed

NCT00715611

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

Phase 2Active Not Recruiting

NCT02838745

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM

Phase 1Terminated

NCT03531840

Olaparib in People With Malignant Mesothelioma

Phase 2Completed

Subject is \>18 years of age

Subject is deemed competent for making medical decisions

Subject is scheduled to undergo chemotherapy followed by surgery and then IMRT

Subject is a surgical candidate

A negative pregnancy test is required in women of child-bearing potential, as standard of care.

You may not qualify if:

Subject is \<18 years old.

Contact the study team to confirm eligibility.

Primary Completion

October 5, 2020

Actual (reported)

Study Completion

October 5, 2020

Actual (reported)

Last Updated

July 30, 2024

Record last verified: 2024-07

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02613312
Data provider: ClinicalTrials.gov
Source updated: 2024-07-30
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:33:59 UTC

Locations

US(1)

Study Stopped

Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations